Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top ...

The federal 340B Drug Pricing Program — a noble idea first enacted in 1992 — needs to be brought back into the shop for ...

Minnesota has becomes the first state to release a report examining the 340B drug discount program for "safety-net" hospitals ...

Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach.

Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...

Discover how the 340B drug pricing program, intended to help low-income patients, has become a system of abuse and misuse ...

Learn about the legal battle between Bristol Myers Squibb and the HHS over the 340B drug pricing program, as other drugmakers join in with rebate plans.

Minnesota releases a report on the 340B Drug Pricing Program, highlighting the need for transparency in healthcare economics.

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...

The 340B Drug Pricing Program allows clinics to buy prescription drugs from drug companies at a discounted price. Claire McGlave, a third-year doctoral student in the School of Public Health, said the ...

Lilly’s lawsuit was filed Thursday in a Washington, D.C. district court against the HHS and the Health Resources and Services ...